CSF-Tau was elevated in PPMS patients in comparison to controls without a significant difference when compared to other RRMS/SPMS (secondary progressive multiple sclerosis) patients [87,88,89]. This evidence concerns the gene MAPT and secondary progressive multiple sclerosis.